Shares of Viking Therapeutics surged nearly 30% following the announcement that their experimental weight loss injection, VK2735, is advancing to a late-stage trial. This San Diego-based biotech company is poised to compete in the lucrative GLP-1 market, projected to reach $150 billion by the decade’s end.
Viking’s Strategic Leap Forward
On Wednesday, Viking Therapeutics revealed plans to expedite their experimental weight loss injection, VK2735, to a phase three trial. “The decision to advance directly to a late-stage trial came after receiving positive feedback from the FDA,” stated CEO Brian Lian during an earnings call. This move positions Viking as a significant contender in the growing GLP-1 market, dominated by giants like Novo Nordisk and Eli Lilly.
Competitive Landscape and Market Potential
The GLP-1 market has witnessed explosive growth, driven by the success of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Viking’s entry could diversify patient options and enhance competition. “Viking’s decision will likely shave a year off the development timeline,” noted BTIG analyst Justin Zelin. Analysts now anticipate VK2735’s market launch by 2029.
Promising Results and Future Studies
VK2735 has shown impressive results in phase two trials, with patients experiencing up to 14.7% body weight loss after 13 weeks. “The results are promising, and we are preparing to meet with the FDA to discuss the design and timing of the phase three trial,” Lian added. Viking also plans to test VK2735 as a monthly injection, potentially offering greater convenience compared to its competitors’ weekly regimens.
Expanding Treatment Options
In addition to the injectable form, Viking is developing an oral version of VK2735. Early-stage trials indicate that the pill version can result in a 3.3% weight loss compared to a placebo. The dual approach of injectable and oral options may provide flexibility and convenience for patients, further solidifying Viking’s position in the weight loss treatment market.
Viking Therapeutics’ rapid progress with VK2735 marks a significant milestone in the competitive landscape of weight loss treatments. Viking offers new hope for those struggling with weight management as they prepare for the phase three trial and explore monthly and oral administration options. Stay tuned for more updates on Viking’s journey and potential impact on the GLP-1 market.
